The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing the impact of PCSK9 inhibition in small cell lung cancer with novel DLL3-targeted bispecific T-cell engager therapy.
 
Laura Alder
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Foundation One Inc; MJH Life Sciences; NuvationBio; OncoHost; Regeneron
Research Funding - BerGenBio; Iambic Pharmaceuticals; ORIC Pharmaceuticals; Phanes Therapeutics
 
Gabrielle Rupprecht
No Relationships to Disclose
 
Jason Somarelli
Research Funding - Pathos AI, TransThera, BMS Celgene, Karyopharm Therapeutics
 
Kaitlin Bevers
No Relationships to Disclose
 
Jeffrey Clarke
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Corbus; G1 Therapeutics; Genentech; Merck; Novartis; Pfizer; Sanofi; Spectrum Pharmaceuticals; Turning Point Therapeutics; Vivacitas Oncology
Speakers' Bureau - Amgen; AstraZeneca
Research Funding - Achilles Therapeutics (Inst); Adaptimmune (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cellular Biomedicine Group (Inst); Genentech (Inst); Grid Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen
(OPTIONAL) Uncompensated Relationships - Lung Cancer Initiative of North Carolina
 
David Hsu
Stock and Other Ownership Interests - Accubeing, Xilis
Patents, Royalties, Other Intellectual Property - MicroOrganoSphere